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Abstract
Background—The interleukin-2 (IL2)-mediated immune response is critical for host defence
against infectious pathogens. CISH, a suppressor of cytokine signalling, controls IL2 signalling.
Methods—We tested for association between CISH polymorphisms and susceptibility to major
infectious diseases (bacteremia, tuberculosis and severe malaria) in 8402 persons from the
Gambia, Hong Kong, Kenya, Malawi, and Vietnam using a case-control design. We have
previously tested twenty other immune-related genes in one or more of these sample collections.
Results—We observed associations between variant alleles of multiple CISH polymorphisms
and increased susceptibility to each infectious disease in each of the study populations. When all
five SNPs (CISH −639, −292, −163, +1320 and +3415) within the CISH-associated locus were
considered together in a multi-SNP score, we found substantial support for an effect of CISH
genetic variants on susceptibility to bacteremia, malaria, and tuberculosis (overall P=3.8 × 10−11)
with CISH −292 being “responsible” for the majority of the association signal (P=4.58×10−7).
Peripheral blood mononuclear cells of adult volunteers carrying the CISH −292 variant showed a
muted response to IL2 stimulation — in the form of 25-40% less CISH — when compared with
“control” cells lacking the −292 variant.
Conclusions—Variants of CISH are associated with susceptibility to diseases caused by diverse
infectious pathogens, suggesting that negative regulators of cytokine signalling may play a major
role in immunity against various infectious diseases. The overall risk of having one of these
infectious diseases was found to be increased by at least 18 percent in individuals carrying the
variant CISH alleles.
Introduction
Tuberculosis, malaria, and invasive bacterial disease together account for over five million
deaths annually in the developing world. Although a significant proportion of inter-
individual variation in disease susceptibility rests on environmental agents such as
malnutrition and infection with HIV, a substantial portion is unexplained. Studies of twins
and adopted persons suggest a genetic component,1 and the genes responsible for many
primary immunodeficiency states have been identified. Such immunodeficiencies are
extremely rare, however, and current understanding of common host genetic factors
influencing susceptibility to major infectious diseases at broad population levels is limited.
A principal feature of the host immune response to infection by structurally diverse
pathogens is the inflammatory cytokine response.2-4 The central pro-inflammatory cytokine
interleukin-2 (IL2) determines the magnitude and duration of the T-cell response
immediately following antigen encounter,5 and assists in the maturation of macrophages,
and the proliferation of B cells and natural killer cells6 in the early stages of the adaptive
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immune response. IL2 also regulates the evolution of memory T cells after resolution of
infection.7 An excessive cytokine-mediated inflammatory response can be harmful to the
host, resulting in severe forms of malaria and sepsis.8-11
Control of cytokine signalling in humans is mediated in part via negative feedback by the
Suppressor of Cytokine Signalling (SOCS) family of proteins. CISH (cytokine inducible
SH-2 domain protein) was the first member of the SOCS family to be described.12,13 CISH
has recently been shown to be the gene most consistently up-regulated by IL2 stimulation in
humans14 and appears to be critical for T-cell proliferation and survival15 in response to
infection. CISH controls the signalling of a variety of cytokines, in particular IL2. Unlike the
other members of the SOCS family, CISH binds to the phosphorylated tyrosine residues of
cytokine receptors through its SH-2 domain and masks sites at which STAT5 would
otherwise dock.12,16-19 Thus, increased CISH activity blocks the cytoplasmic docking and
activation of STAT5, and thereby inhibits downstream cytokine signalling.
Given the central role of CISH in controlling IL2 signaling, we hypothesised that variation
in CISH influences susceptibility to common infectious disease in humans.
Methods
Patient collections
We analyzed 8,402 persons, making up seven case-control series (Table 1). These comprised
Kenyan children with bacteremia,8,20 persons with tuberculosis from Malawi,21 Hong
Kong22 and the Gambia, and persons with severe malaria from the Gambia,23 Kenya,24 and
Vietnam.8 We obtained written informed consent from the study participants and ethical
approval from the relevant national authorities (see Supplementary Appendix) for all study
collections. We obtained blood samples from which we extracted DNA (see Supplementary
Appendix). Control groups were geographically matched to the cases. Twenty other
immune-related genes have been previously studied in one or more of these sample
collections (see Supplementary Table 1).
Genotyping
We used standard methods, details of which can be found in Supplementary information.
Cell stimulation and gene expression study
We purified peripheral blood mononuclear cells (PBMCs) from whole blood drawn from
human volunteers, cultured these cells, and then stimulated them with IL2 or IL3. We
harvested the PBMCs at 0, 0.5 hr, 1 hr and 2 hr time-points after addition of interleukin,
extracted RNAusing a standard method and synthesized and assayed cDNA using real time
PCR (comparative method). Details can be found in Supplementary information.
Statistical analysis
Power calculations for all case-control studies can be found in Supplementary Figure 1.
Comparison of allele frequencies between cases and controls was performed with the
Pearson’s χ2 test under the different genetic modes of inheritance. The most likely mode of
inheritance was determined by best model fit via logistic regression. Detailed descriptions of
the statistical procedures, as well as of the various modes of inheritance are presented in
Supplementary Information. Analysis of pair-wise linkage disequilibrium (LD) between
single nucleotide polymorphisms (SNPs) was performed using the r2 algorithm within
HaploView v3.2.25 Multi-SNP score was analysed as previously described for case-control
populations.26 Individuals were coded accordingly with the number of risk alleles they carry
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(0, 1, 2, 3, or ≥4). A trend test for association was then performed.27 Gene expression data
analysis is located in Supplementary information.
Results
CISH comprises four exons, of which exons 2 to 4 encode the CISH protein. We sequenced
CISH (1,000 base-pairs upstream of the transcription start to the end of exon 4, including
introns) in 24 cases and 24 controls from the Kenyan Bacteraemia (KB) study. Power to
detect SNPs of minor allele frequency (MAF)=0.05 was 99.27% (Supplementary Figure 2).
We identified eight SNPs with a minor allele frequency greater than 5% (Supplementary
Figure3a) and did not detect any novel coding changes or predicted splice-junction variants.
These eight SNPs were then genotyped in the KB case-control study: four of these SNPs (at
positions −639, −292, −163, and +3415) showed evidence of association (P=0.019–
1.0×10−3; Figure 1, Table 2a); the variant alleles at each SNP were associated with increased
susceptibility to bacteremia. Adjusting for HIV status, malnutrition and age did not
significantly affect these associations.
We observed low pair-wise LD between SNPs at positions −639 and +3415, between these
SNPs and those that lie between them, and between the SNPs that lie between them
(r2<0.50; Supplementary Figure 3b). We also observed associations between multiple SNPs
and susceptibility to disease and, bearing in mind the low pair-wise LD between these SNPs,
hypothesized that risk alleles at these SNPs confer susceptibility independent from one
another. To investigate whether risk of disease increased in a dose-dependent manner with
respect to number of risk alleles, we performed multi-SNP scoring for the five SNPs.26 The
risk of bacteremia was found to be proportionate with the number of risk alleles carried
(P=5.1×10−5; Table 2b). Haplotypic analysis was uninformative due to the low inter-marker
LD. We observed no significant evidence of interaction between the five SNPs, and went on
to genotype them in the remaining six case-control studies.
In the Malawian tuberculosis (MTB) study, the minor alleles of three SNPs (-292, +1320,
and +3415) were associated with increased susceptibility to TB (P=0.013-5.0×10−3; Figure
1, Table 2a). For CISH +1320 (overall P=6.0×10−3), the effect of the risk allele appeared
strongest with a recessive mode of inheritance. Individuals homozygous for the risk allele
were significantly more susceptible to tuberculosis compared to matched controls (5.6% of
cases were homozygous for the risk allele, in contrast with 1.9% of controls; P=5.0×10−3).
Adjusting for the potential confounding effects of age, gender, and ethnicity did not affect
the degree of statistical significance and ORs for each SNP. The trend test for increasing
disease risk with increasing number of risk alleles was also positive in this study (P=0.030,
Table 2b). In the Hong Kong TB study (HKTB), those with TB were more likely to carry a
couple of variant CISH alleles (at positions −292 and +1320) than unaffected persons
(P=0.031 and P=2.0×10−3 respectively). In the case-control TB study from the Gambia
(GTB), we observed association between the CISH +1320 variant allele (but not the −292
SNP variant allele) and susceptibility to clinical tuberculosis (P=0.033). The positive trend
test for TB observed in the MTB study was replicated in both HKTB (P=0.011) and GTB
(P=0.034).
We genotyped the five CISH SNPs in three severe malaria collections from Gambia (GM),
Kenya (KM), and Vietnam (VM). The variant alleles at positions −639, −292, +1320 and
+3415 showed significant association with increased susceptibility to disease. In particular,
the minor allele of −292 showed significant association with susceptibility to severe malaria
in GM, KM, as well as the smaller VM study (Table 2a). As was observed in the bacteremia
and tuberculosis studies, the trend test for increasing disease risk with increasing carriage of
CISH risk alleles replicated across all three malaria studies (Table 2b).
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To investigate the possibility that the associated SNPs might be in LD with a true causative
variant elsewhere we performed exclusion mapping by genotyping 28 additional evenly-
spaced SNPs spanning 2,000,000 base-pairs in the Chr3p21 region surrounding CISH in the
Malawi TB study population. None of the additional SNPs typed displayed evidence of
association with TB (Figure 1), suggesting that the observed associations are specific to
CISH.
On pooled analysis, carriage of CISH risk alleles at −639, −292, −163, +1320, and +3415
associated with increased susceptibility to the infectious diseases studied (Table 2a), with
−292 accounting for the majority of the association signal (P=4.58×10−7, Table 2a and
Figure 2). Multi-SNP scoring of the five SNPs in each case-control study revealed that
carriage of ≥1 CISH risk allele is accompanied by increasing risk of disease in each study
(trend P=3.8×10−11, Table 2b).
We studied the functional effects of the CISH promoter variants because these SNPs showed
the strongest associations with disease status and they are more likely to affect gene
expression than intra-genic SNPs. We genotyped the promoter SNPs, SNPs −639, −292 and
−163 in 400 healthy adult volunteers of Chinese descent. The observed risk allele frequency
of CISH −292 and −163 was 41.5% and 6.1% respectively, with only a single volunteer
found to be homozygous for the variant allele at position −163; CISH −639 was non-
polymorphic in these individuals, consistent with observations from the Hong Kong Chinese
case-control studies. We first examined the individual effects of SNPs −292 and −163 on
CISH gene expression in human PBMCs following stimulation with IL2 at a final
concentration of 100U/mL. As expression levels of the wild-type CISH −292A/A and carrier
CISH −292A/T genotypes were similar (P>0.9), we questioned whether this SNP might
exert a recessive effect. As shown in Figure 3a, individuals homozygous for the variant
CISH −292T/T risk genotype (n=10) showed significantly lower levels of CISH when
compared with either those homozygous for alternative allele (A/A)(n=5) or heterozygous
carriers (A/T)(n=10) at 0.5, 1 and 2 hours post-stimulation with IL2. We did not observe any
difference in CISH expression (with respect to CISH −292 genotype) following stimulation
with IL3. Nor did we observe a genotype-specific difference (according to allelic variation
at position −163) after stimulating cells with either IL2 or IL3 (P>0.8, data not shown).
To test for an interactive effect between CISH −292 or CISH −163, we determined two-SNP
(−292 and −163) diplotypes (with chromosomal phase determined via subcloning and
sequencing for individuals whose phase was uncertain) for the subjects analysed for CISH
gene expression, and CISH expression was then compared between the −292 genotypes in
response to IL2 stimulation using −163 as the conditioning locus. For individuals who were
wild-type at −163 (C/C), carrying the variant −292T/T genotype resulted in markedly lower
overall gene expression in response to IL2 stimulation at all time points (Figure 3b). We
observed no significant differences in CISH expression following stimulation by IL2 or IL3
when comparing the other CISH diplotypes with one another (data not shown).
Discussion
We identified a panel of five CISH SNPs associated with increased susceptibility to
bacteremia, tuberculosis and malaria in human populations, and estimated that the overall
risk of having one of these infectious diseases was increased by 18 percent in persons
carrying a single “risk” CISH allele, increasing to 81 percent in those with four or more risk
alleles (Table 2b).
Two important considerations in genetic association studies are population stratification and
multiple testing. To assess the presence of population stratification, we examined 28
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independent markers in the 2-Mb region flanking CISH and did not detect significant
inflation of test statistics (λgc = 1.03). Furthermore, the consistency of the association
across multiple ethnicities argues against the results being a product of population
stratification. Regarding multiple testing, we evaluated CISH in the context of 20 other
immune-related genes (analyzing a total of 187 SNPs) previously tested in one or more of
these sample collections (Supplementary Table 1); the single-point observation with CISH
−292 (P=4.58×10−7) remains significant following correction for all the genes and SNPs
tested (Threshold after correction for multiple-testing: 0.05/500 = 10−4; 187 SNPs tested a
total of 500 times cumulatively). The false-positive-report-probability28 for −292 is ≤10−4
even at prior probability levels of ≤10−5. Further confidence is lent by the very low P-value
(<5×10−11) observed with the multi-SNP score and the level of replication between study
groups.
The pattern of association with CISH −292 was consistently reproducible across six out of
the seven study groups, with the exception being the Gambian TB study. One possible
explanation for this heterogeneity is that disease susceptibility was accounted for by more
than one SNP within the five-SNP panel, thus rendering single SNP analysis incomplete. A
second reason might relate to underlying population structure, where different CISH SNPs
may tag the informative variants in each distinct population. A third possibility is that there
remain unidentified functional SNPs within the region of association delineated by the five-
SNP panel that also account for association with disease. This last possibility is unlikely
however, as direct sequencing did not detect additional putatively functional
polymorphisms. To explore the first and second possibilities, we utilized multi-SNP scoring
for all five associated SNPs. Risk of disease increased markedly with an increase in the
number of risk alleles carried in each population. As this multi-SNP analysis was more
informative than single-point analysis, the above two possibilities remain plausible
explanations. The mechanisms underlying an association between the CISH multi-SNP
score and accompanying dose-dependant effect on disease susceptibility likely reflect the
potential regulatory effect of these polymorphisms within a ‘multi-hit model’, whereby each
‘hit’ affects gene expression cumulatively in aggregate. Such a process is in contrast to
structural variants, where the presence of one deleterious mutation may be sufficient to
account for disease.
In the ex-vivo volunteer study, carriage of the −292 allele reduced CISH expression post-
stimulation with IL2. However, this study lacks power to detect significant differences in
gene expression in individuals with 0, 1, 2, 3, and ≥4 risk alleles. Although −292 showed
associations with multiple infectious diseases and could be a true functional variant, CISH
+1320 showed a stronger association with susceptibility to TB, and showed association in
each of the “TB” studies. The possibility that variation at +1320 affect transcript expression
is possible; this position is located in the untranslated portion of exon 2.29
Further work is required to document the precise mechanisms whereby reduced CISH
expression (and presumably consequential disturbed IL2 signaling) predisposes to increased
risk of infectious disease. Stimulation by IL2 may enhance microbial and viral replication,30
and its effect may be further dependent on the presence of other immune cells: clinical trials
of IL2 infusion in HIV-positive patients have shown different effects on individuals
depending on their CD4+ counts.31,32 Although it is perhaps unexpected that common
variation within a single gene influences susceptibility to a diverse range of infectious
diseases, there is increasing evidence that disparate infections are recognized by a common
host inflammatory pathway. 8,33-35
The observation that the risk alleles occur at appreciable allele frequencies in each of the
study populations is surprising, given evidence suggestive of evolutionary selective pressure
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exerted by some infectious diseases.36,37 One explanation may be that the variant alleles
could have been concurrent modifiers of human susceptibility against other major causes of
mortality in these populations. For example immune modulation at the IL-2 receptor axis
may protect against Type 1 diabetes mellitus;38 a possible role of CISH polymorphisms in
the development of inflammatory as well as infectious diseases merits further study.
Current clinical management of bacteremia, malaria and TB relies primarily on anti-
microbials specifically targeted to the likely pathogen. Our findings implicate CISH in
multi-pathogen susceptibility and raise the possibility that pharmacological manipulation of
the SOCS pathway may impact the treatment of multiple, diverse infectious diseases. CISH
variants may also influence responses to existing immunotherapies, such as IL2 therapy in
renal cell cancer, which is associated with wide and largely unexplained variations in inter-
individual response rates.39,40 Study of longitudinal immune responses together with
responses to antimicrobials and clinical outcome in patients with infectious disease may
further define the risk model for CISH SNPs. The integration of such a model with
environmental and other host genetic factors should improve the prediction of treatment
responses and disease outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank all the patients and volunteers as well as the many investigators involved in the original case-control
studies in The Gambia, Hong Kong, Kenya, Malawi, and Vietnam for their contributions. This work was funded by
the Wellcome Trust and the Agency for Science, Technology and Research (A-STAR), Singapore. CCK is a
scholar of A-STAR. FOV is supported by the EU FP6 GENOSEPT Grant and by the UK ORS Scheme. SJC is a
Wellcome Trust Clinical Research Fellow; TNW, JAS & JAB are Wellcome Trust Clinical Research Fellows, KM
is Director of the Wellcome Trust Kenya Major Overseas Programme. DLMG is supported by an A-STAR
intramural programme grant, AVSH is a Wellcome Trust Principal Fellow.
References
1. Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on
premature death in adult adoptees. N Engl J Med. 1988; 318:727–32. [PubMed: 3347221]
2. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr
Opin Immunol. 2003; 15:450–5. [PubMed: 12900278]
3. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19:93–129. [PubMed:
11244032]
4. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines interleukin-1
beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children
with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy
controls. Infect Immun. 2004; 72:5630–7. [PubMed: 15385460]
5. Aman MJ, Migone TS, Sasaki A, et al. CIS associates with the interleukin-2 receptor beta chain and
inhibits interleukin-2-dependent signalling. J Biol Chem. 1999; 274:30266–72. [PubMed:
10514520]
6. Lin JX, Leonard WJ. Signalling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev.
1997; 8:313–32. [PubMed: 9620644]
7. Dooms H, Wolslegel K, Lin P, Abbas AK. Interleukin-2 enhances CD4+ T cell memory by
promoting the generation of IL-7R alpha-expressing cells. J Exp Med. 2007; 204:547–57. [PubMed:
17312008]
8. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection
against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007;
39:523–528. [PubMed: 17322885]
Khor et al. Page 7
N Engl J Med. Author manuscript; available in PMC 2013 May 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
9. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;
415:673–679. [PubMed: 11832955]
10. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365:63–78. [PubMed:
15639681]
11. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. Streptococcus pneumoniae
anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995;
377:435–438. [PubMed: 7566121]
12. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-
containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors.
EMBO J. 1995; 14:2816–26. [PubMed: 7796808]
13. Uchida K, Yoshimura A, Inazawa J, et al. Molecular cloning of CISH, chromosome assignment to
3p21.3, and analysis of expression in fetal and adult tissues. Cytogenet Cell Genet. 1997; 78:209–
12. [PubMed: 9465889]
14. Jin P, Wang E, Provenzano M, et al. Molecular signatures induced by interleukin-2 on peripheral
blood mononuclear cells and T cell subsets. J. Transl Med. 2006; 4:26. [PubMed: 16805915]
15. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the
gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways.
Immunol Rev. 2004; 202:67–83. [PubMed: 15546386]
16. Matsumoto A, Seki Y, Kubo M, et al. Suppression of STAT5 functions in liver, mammary glands,
and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol. 1999;
19:6396–407. [PubMed: 10454585]
17. Matsumoto A, Masuhara M, Mitsui K, et al. CIS, a cytokine inducible SH2 protein, is a target of
the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997; 89:3148–54. [PubMed:
9129017]
18. Nakajima H, Liu X-W, Wynshaw-Boris A, et al. An indirect effect of Stat5a in IL-2-induced
proliferation: A critical role for Stat5a in IL-2-mediated IL-2 receptor a chain induction.
Immunity. 1997; 7:691–701. [PubMed: 9390692]
19. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression
of peripheral T cells. Immunity. 1999; 10:249–59. [PubMed: 10072077]
20. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in
Kenya. N Engl J Med. 2005; 352:39–47. [PubMed: 15635111]
21. Crampin AC, Mwinuka V, Malema SS, Glynn JR, Fine PE. Field-based random sampling without
a sampling frame: control selection for a case-control study in rural Africa. Trans R Soc Trop Med
Hyg. 2001; 95:481–3. [PubMed: 11706653]
22. Tang NL, Chan PK, Hui DS, et al. Lack of support for an association between CLEC4M
homozygosity and protection against SARS coronavirus infection. Nat Genet. 2007; 39:691–2.
[PubMed: 17534354]
23. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common West African HLA antigens are associated
with protection from severe malaria. Nature. 1991; 352:595–600. [PubMed: 1865923]
24. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N
Engl J Med. 1995; 332:1399–404. [PubMed: 7723795]
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype
maps. Bioinformatics. 2005; 21:263–265. [PubMed: 15297300]
26. Mira MT, Alcais A, Thuc NV, et al. Susceptibility to leprosy is associated with PARK2 and
PACRG. Nature. 2004; 427:636–640. [PubMed: 14737177]
27. Clayton, D. Handbook of Statistical Genetics. Balding, DJ.; Bishop, M.; Cannings, C., editors.
Wiley; New York: 2003. p. 939-960.
28. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability
that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst.
2004; 96:434–42. [PubMed: 15026468]
29. Pickering BM, Willis AE. The implications of structured 5′ untranslated regions on translation and
disease. Semin Cell Dev Biol. 2005; 16:39–47. [PubMed: 15659338]
30. Fauci, AS. Host Factors in the Pathogenesis of HIV Disease. Program and abstracts of the 39th
ICAAC; San Francisco, Calif. September 26-29, 1999; Abstract 614
Khor et al. Page 8
N Engl J Med. Author manuscript; available in PMC 2013 May 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
31. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses
of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N
Engl J Med. 1995; 332:567–75.
32. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected
with the human immunodeficiency virus. N Engl J Med. 1996; 335:1350–6. [PubMed: 8857018]
33. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science. 2003; 300:1524–5.
[PubMed: 12791976]
34. Hawn TR, Dunstan SJ, Thwaites GE, et al. A polymorphism in Toll-interleukin 1 receptor domain
containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis.
2006; 194:1127–34. [PubMed: 16991088]
35. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding
protein gene with childhood infection in consecutive hospital series. BMJ. 1997; 314:1229–32.
[PubMed: 9154025]
36. Tishkoff SA, Varkonyi R, Cahinhinan N, et al. Haplotype diversity and linkage disequilibrium at
human G6PD: recent origin of alleles that confer malarial resistance. Science. 2001; 293:455–62.
[PubMed: 11423617]
37. Barreiro LB, Ben-Ali M, Quach H, et al. Evolutionary dynamics of human Toll-like receptors and
their different contributions to host defense. PLoS Genet. 2009; e1000562
38. Chistiakov DA, Voronova NV, Chistiakov PA. The crucial role of IL-2/IL-2RA-mediated immune
regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal
model studies. Immunol Lett. 2008; 118:1–5. [PubMed: 18417224]
39. McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
Clin Cancer Res. 2007; 13(2):716s–720s. [PubMed: 17255299]
40. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of
inflammatory disease. Immunological Reviews. 2008; 226:19–28. [PubMed: 19161413]
Khor et al. Page 9
N Engl J Med. Author manuscript; available in PMC 2013 May 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1.
Log P-value plot for SNPs typed within CISH (grey highlight) and its 2 Mb flanking region.
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Figure 2.
Forest plots analyses for CISH −292 (rs414171) in all study cohorts. Results of the overall
pooled analysis and case-control analyses were generated using the allelic test. Plots include
the disease odd ratio for the variant allele in each study.
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Figure 3.
a) Differential expression of wild-type (AA; n=5), heterozygote (AT; n=10) and
homozygous mutant (TT; n=10) forms of CISH −292 in response to IL-2. b) Differential
expression of wild-type (AC/AC; n=5), heterozygote (AC/TC; n=5) and homozygous
mutant (TC/TC; n=5) forms of CISH −292 in response to IL-2 in individuals who are wild-
type homozygous (CC) at the −163 locus.
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Table 1
Characteristics of all study cohorts enrolled.
Cohort Country Locality Disease Control Reference
Kenya Bacteremia (KB) Kenya Kilifi Coastal Area 770 560 7, 19
Malawi Tuberculosis (MTB) Malawi Karonga District 335 450 20
Hong Kong TB (HKTB) China Hong Kong City 907 784 21
Gambian TB (GTB) The Gambia Banjul Coastal Area 1309 1427 7
Kenyan Malaria (KM) Kenya Kilifi Coastal Area 685 560* 23
Gambian Malaria (GM) The Gambia Banjul Coastal Area 485 210 22
Vietnam Malaria (VM) Vietnam Ho Chi Minh City 375 105 7
Total 4866 3536 8402
*Shared controls were used for both the Kenyan bacteremia and Kenyan malaria studies.7
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Table 2a
Results of single SNP analysis of CISH −639, −292, −163 and +3415 (per study and pooled).
SNP
ID Study
Sample
size
Best
model
Risk allele
frequency
(affected)d
Risk allele
frequency
(controls)
P-value
Odds
Ratio
(OR)
95% CI for
OR
Pooled
P-valueb
Pooled
OR 95% CI
−639 KB 1326 allelic 0.064 0.04 6.8 × 10−3 1.64 1.14-2.35
MTB 607 allelic 0.036 0.021 0.11 1.76 0.87-3.53
HKTB - - - - - - -
GTB 2690 allelic 0.025 0.024 0.88 1.03 0.68-1.57 1.8 × 10−4 1.49 1.22-1.83
KM 1212 allelic 0.062 0.04 0.017 1.57 1.08-2.28
GM 660 allelic 0.031 0.015 0.093 2.11 0.87-5.11
VM - - - - - - -
−292 KB 1293 allelic 0.412 0.349 1.1 × 10−3 1.31 1.11-1.55
MTB 749 allelic 0.454 0.389 0.013 1.30 1.06-1.61
HKTB 1677 allelic 0.41 0.37 0.031 1.17 1.01-1.34
GTB 2696 allelic 0.282 0.285 0.81 0.99 0.88-1.11 4.58×10−7 1.19 1.12-1.25
KM 1174 allelic 0.39 0.349 0.043 1.19 1.01-1.41
GM 675 allelic 0.282 0.224 0.027 1.36 1.03-1.78
VM 471 dominant 0.41 0.34 0.033 1.60 1.01-2.52
−163 KB 1006 allelic 0.173 0.122 2.0 × 10−3 1.50 1.16-1.95
MTB 629 allelic 0.16 0.135 0.23 1.21 0.88-1.68
HKTB 1316 allelic 0.17 0.18 0.45 0.93 0.76-1.13
GTB 2690 allelic 0.20 0.19 0.64 1.04 0.88-1.22 c c c
KM 995 allelic 0.235 0.122 3.6×10−10e 2.20 1.72-2.84
GM 649 allelic 0.127 0.116 0.58 1.11 0.76-1.63
VM - - - - - - -
+1320 KB 1200 allelic 0.16 0.16 0.99 1.00 0.74-1.35
MTB 819 recessive 0.17 0.16 5.0 × 10−3 2.99 1.27-7.18
HKTB 1691 allelic 0.36 0.31 2.0 × 10−3 1.25 1.08-1.44
GTB 2736 allelic 0.063 0.050 0.033 1.28 1.02-1.62 6.1×10−4 1.17 1.07-1.28
KM 1024 allelic 0.16 0.16 0.99 1.00 0.78-1.28
GM 689 allelic 0.064 0.034 0.022 1.98 1.09-3.57
VM 479 allelic 0.33 0.31 0.58 1.10 0.79-1.53
+3415 KB 1257 allelic 0.242 0.202 0.019 1.26 1.04-1.53
MTB 780 allelic 0.287 0.24 0.039 1.27 1.01-1.59
HKTB 1677 allelic 0.055 0.063 0.31 0.86 0.65-1.15
GTB 2702 allelic 0.22 0.22 0.96 1.00 0.88-1.13 0.010 1.11 1.03-1.20
KM 1189 allelic 0.237 0.202 0.040 1.23 1.01-1.50
GM 684 allelic 0.233 0.205 0.26 1.18 0.89-1.56
VM 478 allelic 0.057 0.049 0.63 1.19 0.59-2.42
N Engl J Med. Author manuscript; available in PMC 2013 May 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Khor et al. Page 15
Table 2b
Meta-SNP analysis of CISH −639, −292, −163, +1320 and +3415 in all study cohorts. Trend tests were
performed for the increasing number of CISH risk alleles (0, 1, 2, 3, or ≥4) carried and increasing odds of
disease susceptibility for each population.
Population specific disease odds ratios
No. of
risk alleles
carried
KB MTB HKTB GTB All TB GM KM VM All Malaria All cohorts
N~1200 N~750 N~1600 N~2700 N~5050 N~650 N~1150 N~480 N~2300 N~8000
0 1 1 1 1 1 1 1 1 1 1
1 1.79 1.00 0.9 1.28 1.12 1.24 0.64 1.58 1.01 1.18
2 1.37 0.88 1.22 1.28 1.20 2.13 0.74 1.65 1.32 1.26
3 2.08 1.54 1.2 1.28 1.29 1.92 1.34 1.38 1.50 1.46
≥4 2.36 1.77 1.43 1.28 1.40 4.19 1.70 - 2.60 1.81
Overall
Trend P 5.1×10
−5 0.030 0.011 0.034 8.7×10−4 4.7×10−3 1.7×10−3 0.13 1.96×10−6 3.8×10−11
KB: Kenyan Bacteraemia study
MTB: Malawian tuberculosis study
HKTB: Hong Kong tuberculosis study
GTB: Gambian tuberculosis study
GM: Gambian malaria study
KM: Kenyan malaria study
VM: Vietnam malaria study
- denotes that the marker was non-polymorphic in that specific population.
b
Both the Tarone and Breslow-Day’s test for homogeneity was not significant across all populations for CISH −639, −292 and +3415 (P>0.4),
indicating that the pooled odds ratio and accompanying pooled P was applicable across all populations. However, for CISH −292, inclusion of the
GTB set causes the tests of homogeneity to be borderline significant (P=0.059). As such, we performed a secondary analysis for −292 which did
not include the GTB set (P = 3.9 × 10−8, OR = 1.23, 95%CI: 1.19-1.34).
c
The Tarone and Breslow-Day’s test for homogeneity was markedly significant (P<0.001) for CISH −163, and thus pooling should not be
performed for this SNP. However, if pooling was performed anyway for the sake of information, P = 3.0×10−7.
d
Risk allele frequency referred to the minor allele frequency for each SNP genotyped. They were the actual allelic frequencies and were not the
result of prediction programs. It was calculated as number of mutant alleles divided by total number of alleles.
eAs this was an apparently highly significant single-point observation, we confirmed the direct sequencing calls by an independent and blinded
person. The concordance rate was absolute, arguing against genotyping error as the cause of this observation.
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